首页 > 市场调查报告书 > 製药

疫苗基因治疗学和RNAi

市场调查报告书

商品编码

1481828

全球 mRNA 疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global mRNA Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月06日 | 出版商:

Value Market Research | 英文 126 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球mRNA疫苗市场需求预计将从2023年的222.3亿美元达到2032年近137.3亿美元的市场规模，2024-2033年研究期间的复合年增长率为-5.21%。

mRNA 疫苗使用信使 RNA (mRNA) 分子来指导体内细胞製造蛋白质，从而刺激针对特定病原体（例如病毒或细菌）的免疫反应。这些疫苗将编码病毒或细菌抗原的合成 mRNA 序列传递到细胞中，将其转化为触发免疫反应的蛋白质抗原。它们不含活病原体，比传统疫苗更安全，并且可以快速开发和生产以应对新出现的传染病。这些疫苗在预防 COVID-19 等传染病的临床试验中显示出有希望的结果，并且正在研究其在治疗癌症和其他疾病方面的潜在应用。

市场动态

应对 COVID-19 大流行的迫切需求加速了 mRNA 疫苗的研究、开发和部署，作为预防病毒感染的一种有前途的方法。 mRNA 疫苗，例如 Pfizer-BioNTech 和 Moderna COVID-19 疫苗，在临床试验和现实世界研究中取得了很高的疗效，可以快速预防 SARS-CoV-2 感染和严重的 COVID-19 疾病。此外，与传统疫苗技术相比，这些疫苗具有多种优势，包括更快的开发时间、可扩展性以及对新兴变种的适应性。此外，应对 COVID-19 大流行的成功引发了人们对各种传染病的兴趣和投资，包括流感、爱滋病毒、兹卡病毒和呼吸道合胞病毒 (RSV)。此外，这些疫苗的潜在应用范围不仅限于传染病，还包括癌症免疫治疗，其中 mRNA 疫苗可以加速免疫系统识别和靶向肿瘤细胞，为个人化癌症治疗提供了一种有前途的方法。此外，製造合作伙伴关係、技术转移协议和产能扩张计划的出现正在加速这些疫苗的全球生产和分销，以满足不断增长的需求并应对供应链挑战。然而，替代疫苗技术的出现以及对长期功效和安全性的担忧可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球 mRNA 疫苗市场的各个细分市场进行了包容性评估。 mRNA 疫苗产业的成长和趋势为本研究提供了整体方法。

市场区隔

mRNA 疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按申请

新冠肺炎
其他的

按最终用户

政府机构
私立医院及诊所
其他（药局等）

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 mRNA 疫苗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 mRNA疫苗市场的主要参与者包括辉瑞公司、Moderna Inc.、诺华公司、赛诺菲、Arcturus、Gennova Biopharmaceuticals Ltd.、艾美疫苗有限公司。、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展等动态。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：mRNA 疫苗公司的竞争格局

mRNA疫苗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Moderna Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

Arcturus

公司简介
公司收入
产品
最近的发展

Gennova Biopharmaceuticals Ltd.

公司简介
公司收入
产品
最近的发展

Aimei Vaccine Co. Ltd

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114452

The global demand for mRNA Vaccine Market is presumed to reach the market size of nearly USD 13.73 Billion by 2032 from USD 22.23 Billion in 2023 with a CAGR of -5.21% under the study period 2024-2033.

mRNA vaccines use messenger RNA (mRNA) molecules to instruct cells in the body to make proteins that stimulate an immune response against specific pathogens, such as viruses or bacteria. These vaccines deliver synthetic mRNA sequences encoding viral or bacterial antigens into cells, translating them into protein antigens that trigger an immune response. They do not contain live pathogens, making them safer than traditional vaccines, and they can be rapidly developed and produced in response to emerging infectious diseases. These vaccines have demonstrated promising results in clinical trials for preventing infectious diseases such as COVID-19 and are being investigated for their potential applications in treating cancer and other diseases.

MARKET DYNAMICS

The urgent need to tackle the COVID-19 pandemic has accelerated the research, development, and deployment of mRNA vaccines as a promising approach to preventing viral infections. mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, have resulted in high efficacy in clinical trials and real-world studies, offering rapid protection against SARS-CoV-2 infection and severe COVID-19 disease. Additionally, these vaccines provide several advantages over traditional vaccine technologies, including faster development timelines, scalability, and adaptability to emerging variants of concern. Moreover, the success in addressing the COVID-19 pandemic has sparked interest and investment in various infectious diseases, including influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). Furthermore, the potential applications of these vaccines extend beyond infectious diseases to include cancer immunotherapy, where mRNA vaccines can accelerate the immune system to recognize and target tumor cells, offering a promising approach to personalized cancer treatment. Additionally, the emergence of manufacturing partnerships, technology transfer agreements, and capacity expansion initiatives is accelerating global production and distribution of these vaccines to meet growing demand and address supply chain challenges. However, the emergence of alternative vaccine technologies and concerns about long-term efficacy and safety may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mRNA Vaccine. The growth and trends of mRNA Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mRNA Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

COVID-19
Others

By End-user

Government Entities
Private Hospitals & Clinics
Others (Pharmacies etc.)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the mRNA Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the mRNA Vaccine market include Pfizer Inc., Moderna Inc., Novartis AG, Sanofi, Arcturus, Gennova Biopharmaceuticals Ltd., Aimei Vaccine Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MRNA VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MRNA VACCINE MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data
5.3. Analysis By Application
5.4. COVID-19 Historic and Forecast Sales By Regions
5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL MRNA VACCINE MARKET ANALYSIS BY END-USER

6.1. Overview By End-user
6.2. Historical and Forecast Data
6.3. Analysis By End-user
6.4. Government Entities Historic and Forecast Sales By Regions
6.5. Private Hospitals & Clinics Historic and Forecast Sales By Regions
6.6. Others (Pharmacies etc.) Historic and Forecast Sales By Regions

7. GLOBAL MRNA VACCINE MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE MRNA VACCINE COMPANIES

8.1. MRNA Vaccine Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF MRNA VACCINE INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Moderna Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Novartis AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Sanofi
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Arcturus
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Gennova Biopharmaceuticals Ltd.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Aimei Vaccine Co. Ltd
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments